Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) hired Eli Kalif as EVP and CFO, effective Dec. 22. He succeeds Michael McClellan, who stepped down Friday for personal reasons. Kalif was SVP, finance at Flex Ltd. (NASDAQ:FLEX).
Ipsen Group (Euronext:IPN; Pink:IPSEY) hired Howard Mayer as EVP and head of R&D, effective Dec. 1, to succeed EVP, R&D and CSO Alexandre Lebeaut, who is retiring at year end. Mayer was SVP, CMO and head of R&D, neuroscience division at Shire plc.
ADC Therapeutics S.A. hired Jennifer Herron as chief commercial officer, a newly created position at the antibody-drug conjugate company. Herron was EVP and chief commercial officer at ImmunoGen Inc. (NASDAQ:IMGN).
HBV company Assembly Biosciences Inc. (NASDAQ:ASMB) hired Luisa Stamm as CMO. She was executive director in the liver diseases therapeutic area at Gilead Sciences Inc. (NASDAQ:GILD).
Kaleido Biosciences Inc. (NASDAQ:KLDO) said William Duke will join the microbiome company as CFO on Nov. 25. Duke was CFO at Pulmatrix Inc. (NASDAQ:PULM).
Lung cancer diagnostics company Biodesix Inc. said COO Scott Hutton will succeed David Brunel as CEO on Jan. 1. Brunel will become chairman.
CorMedix Inc. (NYSE-A:CRMD) and CFO Robert Cook have mutually agreed to not renew Cook's contract, which expires on Jan. 31. The infectious and inflammatory disease company has hired a search firm to identify a new CFO.
Mike Dillon will transition from SVP and CSO of Ideaya Biosciences Inc. (NASDAQ:IDYA) to research fellow in mid-2020. The cancer company also hired Paul Barsanti as VP, head of drug discovery, and Jason Throne as VP, general counsel. Barsanti was an executive in residence at 5AM Ventures, and Throne was VP, general counsel at NeoTract Inc. prior to its acquisition by Teleflex Inc. (NYSE:TFX).
Cancer company Partner Therapeutics, Inc. hired John McManus as CBO. He was CEO of Aeolus Pharmaceuticals Inc. (OTCQX:AOLS).
Randall Kaye joined neuromuscular play Neurana Pharmaceuticals Inc. as CMO. Kaye was CMO of Click Therapeutics Inc.
Odylia Therapeutics Inc., a non-profit company focused on retinal disease gene therapies, hired Ashley Winslow as CSO. She was senior director of portfolio development and translational research at the University of Pennsylvania's Orphan Disease Center.
Non-profit Type I diabetes research organization T1D Exchange made David Walton's interim position as CEO permanent. He has served on the board since 2018 and took on the interim role in April.